DDIWAS: High-throughput electronic health record-based screening of drug-drug interactions
Authors:
- 13 March 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of the American Medical Informatics Association
- Vol. 28 (7) , 1421-1430
Abstract
Objective: We developed and evaluated Drug-Drug Interaction Wide Association Study (DDIWAS). This novel method detects potential drug-drug interactions (DDIs) by leveraging data from the electronic health record (EHR) allergy list. Materials and Methods: To identify potential DDIs, DDIWAS scans for drug pairs that are frequently documented together on the allergy list. Using deidentified medical records, we tested 616 drugs for potential DDIs with simvastatin (a common lipid-lowering drug) and amlodipine (a common blood-pressure lowering drug). We evaluated the performance to rediscover known DDIs using existing knowledge bases and domain expert review. To validate potential novel DDIs, we manually reviewed patient charts and searched the literature. Results: DDIWAS replicated 34 known DDIs. The positive predictive value to detect known DDIs was 0.85 and 0.86 for simvastatin and amlodipine, respectively. DDIWAS also discovered potential novel interactions between simvastatin-hydrochlorothiazide, amlodipine-omeprazole, and amlodipine-valacyclovir. A software package to conduct DDIWAS is publicly available. Conclusions: In this proof-of-concept study, we demonstrate the value of incorporating information mined from existing allergy lists to detect DDIs in a real-world clinical setting. Since allergy lists are routinely collected in EHRs, DDIWAS has the potential to detect and validate DDI signals across institutions.Keywords
Funding Information
- National Institutes of Health (T32GM007347)
- National Institutes of Health (R01 LM010685)
- National Institutes of Health (R01 HL133786)
- National Institutes of Health (T15 LM007450)
- National Institutes of Health (P50 GM115305)
- National Institutes of Health (K12HS026395)
- National Institutes of Health (R35 GM131770)
- American Heart Association (16SDG27490014)
- National Center for Advancing Translational Sciences (2UL1 TR000445-06)
This publication has 50 references indexed in Scilit:
- Criteria for assessing high-priority drug-drug interactions for clinical decision support in electronic health recordsBMC Medical Informatics and Decision Making, 2013
- Data-Driven Prediction of Drug Effects and InteractionsScience Translational Medicine, 2012
- Impact of data fragmentation across healthcare centers on the accuracy of a high-throughput clinical phenotyping algorithm for specifying subjects with type 2 diabetes mellitusJournal of the American Medical Informatics Association, 2012
- Validation of a common data model for active safety surveillance researchJournal of the American Medical Informatics Association, 2012
- Drug allergyAllergy, Asthma & Clinical Immunology, 2011
- Overcoming barriers to NLP for clinical text: the role of shared tasks and the need for additional creative solutionsJournal of the American Medical Informatics Association, 2011
- Normalized names for clinical drugs: RxNorm at 6 yearsJournal of the American Medical Informatics Association, 2011
- Detecting Drug Interactions From Adverse-Event Reports: Interaction Between Paroxetine and Pravastatin Increases Blood Glucose LevelsClinical Pharmacology & Therapeutics, 2011
- Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trialThe Lancet, 2010
- Comparative assessment of four drug interaction compendiaBritish Journal of Clinical Pharmacology, 2006